Cyclacel Pharma (CYCC) Reports Q2 Loss of $1.19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. AXP
10. TMUS

Go back to Cyclacel Pharma (CYCC) Reports Q2 Loss of $1.19

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

August 10, 2016 4:05 PM EDT

BERKELEY HEIGHTS, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported financial results and business highlights for the second quarter ended June 30, 2016.

The Company's net loss applicable to common shareholders for the second quarter ended June 30, 2016 was $3.0 million, or $1.01 per basic and diluted share, compared to net loss applicable to common... More